Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.51 |
| ▸ | UMPS | P11172 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190569 | 0.90 | UMPS (0.54) | P2RX3P2RY2P2RY4UMPSP2RY1 | |
| SCHEMBL29881649 | 0.83 | P2RY1 (0.53) | P2RX3P2RY2P2RY4P2RX2P2RX4 | |
| SCHEMBL18490376 | 0.83 | P2RY1 (0.53) | P2RX3P2RY2P2RY4P2RX2P2RX4 | |
| SCHEMBL10053225 | 0.83 | P2RY1 (0.53) | P2RX3P2RY2P2RY4P2RX2P2RX4 | |
| SCHEMBL10021598 | 0.83 | P2RY1 (0.53) | P2RX3P2RY2P2RY4P2RX2P2RX4 | |
| Deaminoformycin SCHEMBL14217783 | 0.77 | HIF1A (0.46) | UMPS | |
| Deaminoformycin SCHEMBL5071997 | 0.77 | HIF1A (0.46) | UMPS | |
| SCHEMBL29420237 | 0.76 | P2RX1 (0.55) | P2RX3P2RY2P2RX2P2RX4P2RY1 | |
| SCHEMBL18510879 | 0.75 | P2RY2 (0.54) | P2RX3P2RY2P2RY4UMPSP2RX2 | |
| SCHEMBL18079925 | 0.74 | P2RY2 (0.53) | P2RX3P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423143-B2 | Nucleic acid labeling compounds | AFFYMETRIX. INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7291463-B2 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | AFFYMETRIX, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7282327-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050287563-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6965020-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-6864059-B2 | Biotin containing C-glycoside nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20050003496-A1 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | AFFYMETRIX, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040210045-A1 | Nucleic acid labeling compounds | MCGALL GLENN (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040101892-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2004-05-27 | — | — | US | disclosed |
| US-20030180757-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20020165372-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180757-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | P2RX3 3527/4885P2RY2 3816/4885P2RY4 3087/4885 |
| US-20040101892-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | P2RX3 3527/4885P2RY2 3816/4885P2RY4 3087/4885 |
| US-20050287563-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | P2RX3 3527/4885P2RY2 3816/4885P2RY4 3087/4885 |
| US-20020165372-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | P2RX3 3527/4885P2RY2 3816/4885P2RY4 3087/4885 |
| US-20050003496-A1 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | DUT, PCNA, BCDIN3D | P2RX3 4661/4885P2RY2 4360/4885P2RY4 3886/4885 |
| US-20040210045-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | P2RX3 3527/4885P2RY2 3816/4885P2RY4 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.